Astellas Pharma Inc.

4503

JP3942400007

Pharmaceuticals

Delayed Japan Exchange Other stock markets 11:30:00 16/07/2024 am IST			5-day change	1st Jan Change
1,655 ^JPY	-0.12%		+1.56%	-1.84%

02/07	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
03/06	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Astellas Pharma Inc. Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

January 10, 2017 at 08:45 pm IST

Astellas Pharma Inc. announced that it exercised its right to terminate the agreement executed as of September 21, 2010 between Astellas and UMN Pharma Inc. for the co- development and Astellas' exclusive commercialization of ASP7374 and ASP7373, the cell culture based influenza vaccine programs in Japan.

Latest news about Astellas Pharma Inc.

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	02/07	CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	03/06	MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	31/05	CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	21/05	CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	16/05	DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	08/05	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	02/05	MT
Malin Corp investee signs agreement with Astellas Pharma	01/05	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	01/05	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30/04	RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024	25/04
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	25/04	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	25/04	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	25/04	CI
Astellas Pharma Inc. Announces Board and Committee Retirements	25/04	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	25/04	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	24/04	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22/04	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22/04	CI
Lupin Launches Mirabegron Extended-Release Tablets in US	22/04	MT
Japan Inc makes a renewed U.S. push as China fears mount	17/04	RE
Middle East Tensions Blunt Asian Stock Markets Excepting China	15/04	MT
Astellas Pharma Cuts Attributable Profit Forecast for Fiscal Year Ended March	15/04	MT
Japan's Nikkei sags as Iran attack, Wall Street sell-off sour sentiment	15/04	RE
Japan's Nikkei drops 1% as Iran attack, Wall Street sell-off fuel risk aversion	15/04	RE

Chart Astellas Pharma Inc.

Duration

Period

More charts

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q1 2024 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,657 JPY

Average target price

1,845 JPY

Spread / Average Target

+11.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTELLAS PHARMA INC.	-1.84%	1.88TCr
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+38.73%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+13.40%	24TCr
ROCHE HOLDING AG	+5.19%	23TCr
NOVARTIS AG	+16.32%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals